Entity

Time filter

Source Type


Yang Z.,Lu Daopei Hematology and Oncology Center | Hongxing L.,Lu Daopei Hematology and Oncology Center
Journal of Leukemia and Lymphoma | Year: 2015

The event free survival and overall survival rate of acute lymphoblastic leukemia (ALL) have been improved significantly based on the risk stratify diagnosis and treatment. But there are still some patients suffering therapeutic failure and relapse. With the great development of genome sequencing technology, more and more genetic aberrations behind the refractory and relapse ALL have been identified. Ph-like ALL is charactered with gene expression profile similar to that of BCR-ABLl positive ALL, involving abnormal activation of cytokine receptor and tyrosine kinase. It has been proved that treatment combined with Tyrosine kinase inhibitors (TKIs) can significantly improve the poor prognosis. Ph-like ALL is one of hot topics during the 56th American Society of Hematology (ASH) annual meeting in 2014. Progression in molecular genetics for Ph-like ALL will be introduced together with the author's research experience. © 2015 Editorial Board of Journal of Leukemia and Lymphoma. All rights reserved.


Xue C.,Lu Daopei Hematology and Oncology Center | Hongxing L.,Lu Daopei Hematology and Oncology Center
Journal of Leukemia and Lymphoma | Year: 2015

With the progress of medical research, more and more inherited and congenital factors predisposing to hematologic malignancies have been revealed, which have brewed into a hot topic of the 56th American Society of Hematology (ASH) annual meeting in 2014. Correctly understanding and interpreting these innate susceptible factors will be of great significance in improving the treatment in patients and prevention or early detecting of cancers in individuals carrying these factors. Research progress in this area will be introduced together with the authors' research in this article. © 2015 Editorial Board of Journal of Leukemia and Lymphoma. All rights reserved.


Xue C.,Lu Daopei Hematology and Oncology Center | Yang Z.,Lu Daopei Hematology and Oncology Center | Hongxing L.,Lu Daopei Hematology and Oncology Center
Journal of Leukemia and Lymphoma | Year: 2015

The detection of JAK2 V617F and CALR mutations, which was first reported in 2005 and 2013, respectively, had greatly improved the diagnosis and treatment of myeloproliferative neoplasms (MPN). Most MPN patients are inclined to thrombophilia, the carrier frequency of JAK2 V617F mutation was also high in patients of various thrombotic events, and the relationship between the two conditions needs further study. The observation of JAK2 V617F mutation in control group and general population also enlightened and changed the understanding about the development of chronic cancer. Research progress in this area will be introduced together with the related reports in the 56th American Society of Hematology annual meeting in 2014. © 2015 by the Chinese Medical Association.


Biping D.,Lu Daopei Hematology and Oncology Center | Hongxing L.,Lu Daopei Hematology and Oncology Center | Chunrong T.,Lu Daopei Hematology and Oncology Center
Journal of Leukemia and Lymphoma | Year: 2015

Chimeric antigen receptor T cell (CAR-T) therapy has shown promising perspective in clinical trails of B cell hematologic malignancies. Meanwhile, this therapy still need to be further improved in the following aspects: design of CAR-T, cancer antigens selection, T cells origin, and clinical application strategy. CAR-T immunotherapy is one of hot topics in the 56th American Society of Hematology (ASH) annual meeting. Some breakthroughs have been reported in both basic research and clinical trails. © 2015 Editorial Board of Journal of Leukemia and Lymphoma. All rights reserved.

Discover hidden collaborations